TTCC-GrupoTratamiento Tumores Cabeza y Cuello
@ttccgroup
Followers
1K
Following
6K
Media
274
Statuses
3K
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello - Spanish Head and Neck Cancer Cooperative Group- 2001
España - Spain
Joined February 2015
Enorme orgullo la colaboración de @ttccgroup con GORTEC en el ensayo NIVOPOST OP presentado en la sesión plenaria de #ASCO25 que supondrá un cambio en la práctica clínica del cáncer de cabeza y cuello @FundacionTTCC
1
12
20
RT @PaulJiL: 🚨Update in Head&Neck SCC @NCCN Evidence Blocks . 💉neoadjuvant #pembrolizumab added!.Highlighting indication for resectable st….
0
17
0
Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial | JCO Oncology Advances
ascopubs.org
PURPOSEImpaired homologous recombination–mediated DNA repair is common in head and neck squamous cell carcinoma (HNSCC) and in preclinical models and sensitizes HNSCC to poly (ADP-ribose) polymerase...
0
1
6
RT @Larvol: On Head and Neck Cancer Day, we’re sharing key anticipated milestones expected in 2025. 🔗 Follow us for latest clinical trials….
0
16
0
RT @ContraCancerEs: Hoy, 27 de julio, #DíaMundialCáncerCabezayCuello, destacamos el proyecto de la Dra. Natalia Sanz @IIBmCSICUAM para ava….
0
14
0
RT @SEORLCCC: 📈 El VPH provoca entre el 30 y el 70% de los tumores de orofaringe. 🔴En 2025 se diagnosticarán 7.446 cánceres de la cavidad o….
0
5
0
RT @NoInvisibles: Es #DiaMundialCancerCabezayCuello.Un bulto en el cuello, una llaga en la boca que no cura, dificultad o dolor al tragar o….
0
35
0
RT @fundacionmutua: En el Institut d’Investigacio en Ciencies de la Salut @GTRecerca (Badalona), la Dra. Beatriz Cirauqui liderará el “Proy….
0
3
0
RT @fundacionmutua: Con nuestras #AyudasFundaciónMutua impulsamos proyectos colaborativos en los que participan hospitales de cuatro o más….
0
5
0
RT @fundacionmutua: En la XXII Convocatoria de #AyudasFundaciónMutua a la investigación médica impulsaremos 23 proyectos científicos que se….
0
9
0
RT @NEJM: Original Article: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (KEYNOTE-689 phase 3 trial) htt….
0
26
0
RT @JAMAOto: Neoadjuvant therapy, enhanced by anti–PD-1 immunotherapy, shows promise for precision head and neck oncology, but further tria….
0
8
0
RT @JAMAOto: In patients 70 years and older undergoing surgical treatment for oropharyngeal carcinoma, HPV-positive status determined by p1….
0
7
0
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | New England Journal of Medicine
nejm.org
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unc...
0
6
10
NIVOPOSTOP Trial Demonstrates DFS Benefit of Adjuvant Nivolumab in High-Risk HNSCC Following Chemoradiotherapy
dailynews.ascopubs.org
NIVOPOSTOP results show that adding nivolumab to standard adjuvant chemoradiotherapy after surgery significantly improves DFS in patients with high-risk locally advanced head and neck squamous cell...
0
6
11
Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus–Negative, Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm, Phase II Trial | JCO Precision Oncology
ascopubs.org
PURPOSEThe primary aim of this single-arm, phase II trial was to determine the objective response rate (ORR) with palbociclib, a selective CDK4/6 inhibitor, administered before chemoradiotherapy...
0
7
7
RT @OlivaM_Onc: Presentando la CyC-APP en representación de la @FundacionTTCC en la Reunión de Primavera @SEORLCCC 💫! Gracias por la invit….
0
7
0
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma | Journal of Clinical Oncology
ascopubs.org
PURPOSEContinued improvement in outcomes is needed for advanced cutaneous squamous cell carcinoma (cSCC).MethodsAlliance A091802 is a randomized phase II trial of avelumab (800 mg IV once every 2...
0
3
3